93 patents
Page 2 of 5
Utility
RNAi therapy for hepatitis B virus infection
27 Dec 22
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Christine I. Wooddell, David B. Rozema, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
Filed: 9 Sep 20
Utility
Trialkyne Linking Agents and Methods of Use
22 Dec 22
Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides.
Zhen Li, Erich Altenhofer, Jeffrey Carlson, Matthew Fowler-Watters, Bo Chen
Filed: 15 Feb 19
Utility
RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use
15 Dec 22
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene.
Anthony Nicholas, Erik W. Bush, David Itiro Kasahara, Casi M. Schienebeck
Filed: 7 Apr 22
Utility
RNAi agents for Hepatitis B virus infection
6 Dec 22
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Zhen Li, Rui Zhu, Christine I. Wooddell, Bruce D. Given, Tao Pei, David L. Lewis, Lauren J. Almeida, David B. Rozema, Darren H. Wakefield
Filed: 17 Nov 21
Utility
Organic Compositions to Treat HSF1-RELATED Diseases
1 Dec 22
The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
Gregory Hinkle, Satyanarayana Kuchimanchi, Stuart Milstein, Markus Warmuth, Wenlai Zhou, Ping Zhu, Tracy S. Zimmermann
Filed: 6 Apr 22
Utility
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
17 Nov 22
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Jon E. Chatterton, David P. Bingaman
Filed: 15 Jun 22
Utility
RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
8 Nov 22
Described herein are compositions and methods for inhibition of Asialoglycoprotein receptor 1 (ASGR1) gene expression.
Zhen Li, Tao Pei, Rui Zhu, Bruce D. Given, Stacey Melquist
Filed: 16 Oct 18
Utility
Methods for the Treatment of ALPHA-1 Antitrypsin Deficiency (Aatd)
29 Sep 22
Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents.
Bruce Given, Dawn Christianson, James C. Hamilton, Zhen Li, Rui Zhu, Christine Wooddell, Tao Pei
Filed: 5 Jun 20
Utility
RNAi Inhibition of Alpha-ENaC Expression
28 Jul 22
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
Filed: 5 Apr 22
Utility
Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin
12 Jul 22
The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference.
Christine I Wooddell, David L Lewis, Darren H Wakefield, Lauren Almeida, Steven B Kanner
Filed: 31 May 19
Utility
RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use
30 Jun 22
The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha (EPAS1) gene expression.
Zhen Li, Dongxu Shu, Anthony Nicholas, Rui Zhu, Jeffrey Carlson, So Wong, Xiaokai Li, Erich Altenhofer, Matthew Fowler-Watters, Bo Chen
Filed: 8 Jan 20
Utility
ALPHA-1 Antitrypsin (Aat) Rnai Agents, Compositions Including Aat Rnai Agents, and Methods of Use
2 Jun 22
RNAi agents for inhibiting the expression of the alpha-1 antitrypsin (AAT) gene, compositions including AAT RNAi agents, and methods of use are described.
Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei
Filed: 10 Nov 21
Utility
RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
26 May 22
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Jon E. Chatterton, David P. Bingaman
Filed: 7 Feb 22
Utility
5'-Cyclo-Phosphonate Modified Nucleotides
21 Apr 22
Described are 5′-cyclo-phosphonate modified nucleotides, and oligonucleotides, such as interference (RNAi) agents, containing 5′-cyclo-phosphonate modified nucleotides.
Zhen Li, Tao Pei, Michael Lawler
Filed: 30 Jun 21
Utility
RNAi Inhibition of Alpha-ENaC Expression
14 Apr 22
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
Filed: 23 Dec 21
Utility
RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use
24 Mar 22
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene.
Zhen Li, Rui Zhu, Tao Pei, Anthony Nicholas, Erik W Bush
Filed: 29 Nov 21
Utility
Rnai Agents for Hepatitis B Virus Infection
17 Mar 22
Described are compositions and methods for inhibition of Hepatitis B virus gene expression.
Zhen LI, Rui ZHU, Christine I. WOODDELL, Bruce D. GIVEN, Tao PEI, David L. LEWIS, Lauren J. ALMEIDA, David B. ROZEMA, Darren H. WAKEFIELD
Filed: 17 Nov 21
Utility
RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)
3 Mar 22
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents.
Zhen Li, Rui Zhu, Tao Pei, Steven Kanner, So Wong
Filed: 18 Nov 21
Utility
Organic compositions to treat EPAS1-related diseases
1 Mar 22
The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preeclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.
Brian Bettencourt, Shanthi Ganesh, Elizabeth George, Dieter Huesken, Stuart Milstein, Jonathan Solomon, Emily Thomas, Ivanka Toudjarska, Jennifer Tullai, Jan Weiler
Filed: 21 Jan 20
Utility
RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use
24 Feb 22
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit 17P-hydroxy steroid dehydrogenase type 13 (HSD17B13 or 17β-H8013) gene expression.
Zhen Li, Rui Zhu, Shawn A Morales
Filed: 18 Sep 19